非酒精性脂肪性肝病与右冠状动脉周围脂肪组织CT衰减对急性胸痛患者的预后价值
回顾性纳入2011年1月至2021年12月连续急诊因急性胸痛行冠状动脉CT血管成像的患者514例,中位随访31个月,60例(11.67%)发生主要不良心血管事件(MACE)。多变量Cox回归显示非酒精性脂肪性肝病(NAFLD,HR=2.599)和右冠状动脉周围脂肪组织CT衰减(HR=1.026)均为MACE独立预测因子。全局卡方分析显示NAFLD在临床危险因素和CCTA指标之上(59.51 vs 54.44,P=0.024)及在RCA PCAT CT衰减之上(63.75 vs 59.51,P=0.040)均提供增量预后价值。
要点
- NAFLD(HR=2.599)与RCA PCAT CT衰减(HR=1.026)均为急性胸痛患者MACE独立预测因子。
- NAFLD较RCA PCAT CT衰减对MACE具有增量预后价值(全局卡方63.75 vs 59.51,P=0.040)。
核心结论
- NAFLD和RCA PCAT CT衰减是急性胸痛患者MACE的预测因子,NAFLD在RCA PCAT CT衰减之上对MACE具有增量预后价值;作者认为将CT-FFR纳入急性胸痛患者风险预测值得考虑。
研究设计与样本
- 回顾性研究,连续纳入2011年1月至2021年12月急诊因急性胸痛转诊行冠状动脉CT血管成像(CCTA)的患者514例(平均年龄58.36±13.05岁,男性310例),中位随访31个月。
诊断标准与关键数值
- MACE定义包括需住院的不稳定型心绞痛、冠状动脉血运重建、非致死性心肌梗死和全因死亡,随访期间60例(11.67%)发生MACE。
- NAFLD预测MACE的HR=2.599(95%CI:1.207,5.598,P=0.015),RCA PCAT CT衰减预测MACE的HR=1.026(95%CI:1.001,1.051,P=0.038)。
- 全局卡方分析:NAFLD较临床危险因素和CCTA指标提高MACE风险预测(59.51 vs 54.44,P=0.024),NAFLD联合RCA PCAT CT衰减较单用RCA PCAT CT衰减提高MACE风险预测(63.75 vs 59.51,P=0.040)。
临床应用与阅片要点
- 在急性胸痛患者CCTA评估中,可同时评估NAFLD和RCA PCAT CT衰减以辅助MACE风险分层。
- 作者认为将CT-FFR纳入急性胸痛患者风险预测值得考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Pericoronary adipose tissue (PCAT) CT attenuation of right coronary artery (RCA) and non-alcoholic fatty liver disease (NAFLD) have prognostic value for major adverse cardiovascular events (MACE) in patients with coronary artery disease. However, the superior prognostic value between RCA PCAT CT attenuation and NAFLD remains unclear in patients with acute chest pain. This study is to evaluate the prognostic value of NAFLD for MACE, and further assess the incremental prognostic value of NAFLD over PCAT CT attenuation.
MATERIALS AND METHODS: Between January 2011 and December 2021, all consecutive emergency patients with acute chest pain referred for coronary CT angiography (CCTA) were retrospectively enrolled. MACE included unstable angina requiring hospitalization, coronary revascularization, non-fatal myocardial infarction, and all-cause death. Patients' baseline and CCTA characteristics, RCA PCAT CT attenuation, and the presence of NAFLD were used to evaluate risk factors of MACE using multivariable Cox regression analysis. The prognostic value of NAFLD compared to RCA PCAT CT attenuation was analyzed.
RESULTS: A total of 514 patients were enrolled (mean age, 58.36 ± 13.05 years; 310 men). During a median follow-up of 31 months, 60 patients (11.67%) experienced MACE. NAFLD (HR = 2.599, 95% CI: 1.207, 5.598, P = 0.015) and RCA PCAT CT attenuation (HR = 1.026, 95% CI: 1.001, 1.051, P = 0.038) were independent predictors of MACE. The global Chi-square analysis showed that NAFLD improved the risk of MACE more than that using clinical risk factors and CCTA metrics (59.51 vs 54.44, P = 0.024) or combined with RCA PCAT CT attenuation (63.75 vs 59.51, P = 0.040).
CONCLUSION: NAFLD and RCA PCAT CT attenuation were predictors of MACE. NAFLD had an incremental prognostic value beyond RCA PCAT CT attenuation for MACE in patients with acute chest pain. Adding CT-FFR into the risk prediction of patients with acute chest pain is worth considering.
引用
- Yang W, Wen D, Li S, et al. Prognostic Value of Non-alcoholic Fatty Liver Disease and RCA Pericoronary Adipose Tissue CT Attenuation in Patients with Acute Chest Pain. Acad Radiol. 2023. PMID: 38160090. doi:10.1016/j.acra.2023.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。